Lupus Treatment
-
SAPHNELO approved in the US for subcutaneous self-administration for treatment of systemic lupus erythematosus (SLE)
.
The U.S. Food & Drug Administration (FDA) has granted approval for subcutaneous administration of anifrolumab (SAPHNELO) for treatment of people living with moderately to severely active autoantibody-positive systemic lupus erythematosus (SLE). The 120 mg dose of the therapy…